Please ensure Javascript is enabled for purposes of website accessibility

Why Fulcrum Therapeutics Popped Again on Tuesday

By Cory Renauer – Updated Aug 11, 2021 at 4:07PM

Key Points

  • Fulcrum Therapeutics told investors it started a $100 million share offering to support the development of its lead candidate, FTX-6058.
  • Analyst upgrades in response to initial clinical-trial data the company released yesterday pushed the stock more than 30% higher this morning, but the rally ran out of gas.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.

What happened

Fulcrum Therapeutics (FULC -0.92%) shares are climbing again after the early clinical-stage biotech announced a plan to raise $100 million in a secondary share offering. Investors aren't thrilled about the share offering, but upgrades from Wall Street analysts helped them get over it and then some.

The stock was up more than 35% this morning, but the rally has stalled. Shares of Fulcrum Therapeutics were ahead just 3.9% at 3:13 p.m. EDT on Wednesday.

So what 

Yesterday, Fulcrum Therapeutics stock shot up after the company read out compelling results from the first clinical trial with its first new drug candidate, tentatively named FTX-6058. This is a once-daily pill that encourages the production of fetal hemoglobin (HbF) in order to help people born with sickle cell disease (SCD). 

Scientist looking through a microscope while holding two test tubes.

Image source: Getty Images.

Fulcrum Therapeutics is trying to turn the world of drug development on its head by using artificial-intelligence algorithms to elucidate targets to aim new drugs at. We don't know if FTX-6058 will help SCD patients reduce their reliance on blood transfusions, but signs the company shared from a trial with healthy volunteers suggest it can provide a significant benefit.

Now what

Red blood cells of SCD patients lose their round shape because hemoglobin, the oxygen-carrying protein the cells contain, isn't as stable as it needs to be. There are complicated gene therapies in development now for SCD, but none are attacking the problem from the same angle as Fulcrum Therapeutics.

FTX-6058 is meant to treat SCD by helping patients begin producing HbF, which it appeared to do for healthy volunteers. People who received a 10-milligram pill once a day for 14 days had 4.2 times as many HbF-containing blood cells as they did before beginning treatment.

Sickle cell disease is rare, but there are more than enough patients underserved by available care to drive sales up past $1 billion annually within a couple of years after launching. We'll know a lot more about FTX-6058 around the middle of next year. In the fourth quarter, Fulcrum Therapeutics intends to begin a trial with SCD patients and a treatment period of up to three months. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Fulcrum Therapeutics, Inc. Stock Quote
Fulcrum Therapeutics, Inc.
$6.50 (-0.92%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.